Madrigal Pharmaceuticals Inc (MDGL)
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing therapies for metabolic dysfunction-associated steatohepatitis, or MASH, in the United States. The company’s lead product is Rezdiffra, a liver-directed thyroid hormone receptor beta agonist approved for the treatment of MASH. Madrigal Pharmaceuticals was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania. Its common stock trades on the NASDAQ under the ticker MDGL.
Stock Summary
Fair Value
Profitability & Growth
Quality & Risk
Events & Dividends
Technical Outlook
FAQ
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
Data update note:
Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-MDGL
|
$619.90
|
14.4% Upside
|
Fair
|
$678.86
|
25.3% Upside
|
Undervalued
|
Good
|
—
|
—
|
—
|
0.0%
|
July 30, 2026
|
-40.6x
|
23.1x
|
11.1x
|
12.351 B
|
12.09 B
|
2.7%
|
60.7%
|
9.2
|
—
|
88.0%
|
